EA004179B1 - Способ лечения неопластического заболевания при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата - Google Patents

Способ лечения неопластического заболевания при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата Download PDF

Info

Publication number
EA004179B1
EA004179B1 EA200100168A EA200100168A EA004179B1 EA 004179 B1 EA004179 B1 EA 004179B1 EA 200100168 A EA200100168 A EA 200100168A EA 200100168 A EA200100168 A EA 200100168A EA 004179 B1 EA004179 B1 EA 004179B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
compound
alkyl
group
pharmaceutical composition
Prior art date
Application number
EA200100168A
Other languages
English (en)
Russian (ru)
Other versions
EA200100168A1 (ru
Inventor
Станислав Р. Бурзинский
Original Assignee
Станислав Р. Бурзинский
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Станислав Р. Бурзинский filed Critical Станислав Р. Бурзинский
Publication of EA200100168A1 publication Critical patent/EA200100168A1/ru
Publication of EA004179B1 publication Critical patent/EA004179B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
EA200100168A 1998-07-23 1999-07-02 Способ лечения неопластического заболевания при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата EA004179B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (2)

Publication Number Publication Date
EA200100168A1 EA200100168A1 (ru) 2001-08-27
EA004179B1 true EA004179B1 (ru) 2004-02-26

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100168A EA004179B1 (ru) 1998-07-23 1999-07-02 Способ лечения неопластического заболевания при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата

Country Status (20)

Country Link
US (2) US6258849B1 (enExample)
EP (1) EP1098643B1 (enExample)
JP (2) JP2002521329A (enExample)
KR (4) KR100414587B1 (enExample)
CN (3) CN1605334A (enExample)
AT (1) ATE257378T1 (enExample)
AU (1) AU759278B2 (enExample)
BR (1) BR9912356A (enExample)
CA (1) CA2336945C (enExample)
DE (1) DE69914084T2 (enExample)
DK (1) DK1098643T3 (enExample)
EA (1) EA004179B1 (enExample)
ES (1) ES2214866T3 (enExample)
ID (1) ID28160A (enExample)
IL (1) IL140848A (enExample)
NZ (1) NZ509244A (enExample)
PL (1) PL213698B1 (enExample)
PT (1) PT1098643E (enExample)
WO (1) WO2000004894A2 (enExample)
ZA (1) ZA200100622B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
ATE311358T1 (de) * 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
EP3397960B1 (en) * 2015-12-30 2020-01-29 Société des Produits Nestlé S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
EA202090024A1 (ru) * 2017-06-12 2020-04-10 Станислав Р. Бурзинский Способы лечения лептоменингеального заболевания
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
DE69734713T2 (de) 1996-05-14 2006-07-06 Burzynski, Stanislaw R., Houston Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
KR100417101B1 (ko) 2004-02-05
KR20010071025A (ko) 2001-07-28
EP1098643B1 (en) 2004-01-07
ZA200100622B (en) 2002-06-26
ID28160A (id) 2001-05-10
US6943192B2 (en) 2005-09-13
US20010044466A1 (en) 2001-11-22
EP1098643A2 (en) 2001-05-16
WO2000004894A3 (en) 2000-04-27
DK1098643T3 (da) 2004-05-24
NZ509244A (en) 2004-02-27
KR20030027087A (ko) 2003-04-03
AU4854299A (en) 2000-02-14
PL213698B1 (pl) 2013-04-30
US6258849B1 (en) 2001-07-10
BR9912356A (pt) 2001-04-17
CN1605334A (zh) 2005-04-13
WO2000004894A2 (en) 2000-02-03
KR100417100B1 (ko) 2004-02-05
IL140848A0 (en) 2002-02-10
EA200100168A1 (ru) 2001-08-27
DE69914084D1 (de) 2004-02-12
KR20030027089A (ko) 2003-04-03
CA2336945A1 (en) 2000-02-03
CN1660061A (zh) 2005-08-31
CN1319010A (zh) 2001-10-24
CA2336945C (en) 2008-11-18
KR100399658B1 (ko) 2003-09-29
DE69914084T2 (de) 2004-10-28
PT1098643E (pt) 2004-05-31
KR20030027088A (ko) 2003-04-03
JP2011051993A (ja) 2011-03-17
CN1191064C (zh) 2005-03-02
ATE257378T1 (de) 2004-01-15
PL345959A1 (en) 2002-01-14
ES2214866T3 (es) 2004-09-16
JP2002521329A (ja) 2002-07-16
AU759278B2 (en) 2003-04-10
CN100400039C (zh) 2008-07-09
IL140848A (en) 2005-05-17
HK1037142A1 (en) 2002-02-01
KR100414587B1 (ko) 2004-01-13

Similar Documents

Publication Publication Date Title
EP1098643B1 (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
Bertaccini Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat
BR112020014202A2 (pt) compostos de 1,2,4-oxadiazol como inibidores de vias de sinalização cd47
SG10202109849SA (en) Compositions and methods for modulating hair growth
HK1201730A1 (en) Treatment agent and/or prophylactic agent for side effects of cancer drugs
CN102180832A (zh) 脑缺血保护用化合物及制备方法
US6451761B1 (en) N′N′-dichlorinated omega-amino acids and uses thereof
US4918193A (en) Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion
JP2020019722A (ja) 神経障害性疼痛の医薬組成物
US20130338165A1 (en) Use of Compounds Elevating Glutathione Levels for the Treatment of Parkinson's Disease
Smith et al. The pharmacologic and chemotherapeutic action of some new sulfones and streptomycin in experimental tuberculosis
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
WO1994005271A1 (en) Gastrointestinal cancer therapy composition containing dimethylsulphone and dimethylsulphoxide
WO1994005292A1 (en) Gastrointestinal treatment compositions containing allopurinol or oxypurinol and a sulphydryl group releasing agent
Wilson The effect of fenfluramine on alcohol consumption
CH507004A (fr) Procédé de préparation d'un médicament contenant les dérivés cycliques de la cystéine destiné au traitement des processus de vieillissement prématuré et des troubles du métabolisme des substances thioliques
JPH03190822A (ja) 抗炎症活性を有する新規な製薬組成物
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU